Taro Recalls Desoximetasone Cream Due to Stability Issues
Taro Pharmaceuticals recalls specific lots of Desoximetasone Cream USP 0.25% due to failed stability specifications. Check your lot numbers and expiration dates.
Use caution until it’s fixed
Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
Contact the company
What happened, in plain English
Taro Pharmaceuticals is recalling Desoximetasone Cream USP, 0.25% in 100 g tubes because the product failed stability specifications for homogeneity. The affected lots showed moderate separation, which may affect the medication's uniformity. No remedy or return instructions are currently listed in the record. Read more at govinfonow.com/recall/42441-taro-recalls-desoximetasone-cream-due-to-stability-issues.
Source Summary by GovInfoNow · govinfonow.com/recall/42441-taro-recalls-desoximetasone-cream-due-to-stability-issues · Updated October 11, 2026 · FDA enforcement record: FDA #D-0116-2017
Cite this page
“Taro Recalls Desoximetasone Cream Due to Stability Issues.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/42441-taro-recalls-desoximetasone-cream-due-to-stability-issues. Based on FDA recall #D-0116-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0116-2017%22&limit=1).
Why it’s dangerous
The recall is due to failed stability specifications where the cream exhibited out-of-specification results for homogeneity, specifically moderate separation. This means the active ingredient may not be evenly distributed throughout the tube, potentially leading to inconsistent dosing.
Who’s affected
Consumers and patients who purchased Desoximetasone Cream USP from pharmacies in the United States and Puerto Rico between the manufacture date and September 13, 2016. Individuals using these specific lot numbers are at risk of receiving a product with potential separation issues.
How to tell if you have this one
Check your tube of Desoximetasone Cream USP, 0.25% 100 g, Rx only, manufactured by Taro Pharmaceuticals Inc. Look for NDC 51672-1270-7 and one of the following lot numbers: B5093-18608 (Exp Jan 2017), B5094-18608 (Exp Jan 2017), C5141-18954 (Exp Feb 2017), C5142-18954 (Exp Feb 2017), or E5109-19625 (Exp Feb 2017).
- Brand
Taro Pharmaceuticals- Category
Drug
All 2 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Terminated- Distribution
US & Puerto Rico- NDC
51672-1271-1, 51672-1271-2, 51672-1271-3, 51672-1271-7, 51672-1270-1, 51672-1270-2, 51672-1270-3, 51672-1270-7, 51672-1261-1, 51672-1261-2, 51672-1261-3
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-0116-2017 | Desoximetasone Cream USP, 0.25% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1270-7; Lot #: B5093-18608, B5094-18608, Exp. Jan 2017; Lot #: C5141-18954, C5142-18954, E5109-19625, Exp . Feb 2017 | 15,576 units |
| D-0117-2017 | Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1271-7; Lot #: E0598-19624, E5099-19624, Exp. Jan 2017 | 6,756 units |
What to do — step by step
Check Your Lot Numbers
Verify if your tube matches the recalled lot numbers B5093-18608, B5094-18608, C5141-18954, C5142-18954, or E5109-19625.
Contact Your Pharmacist
Since no specific remedy is listed in the record, consult your pharmacist or healthcare provider for guidance on what to do with the product.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “US & Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0116-2017 (September 13, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0116-2017 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.